CJC-1295 & Ipamorelin
The Walker 2006 CJC-1295 Study
Teichman et al. (Journal of Clinical Endocrinology & Metabolism, 2006) reported the first controlled pharmacokinetic study of CJC-1295 with DAC in healthy adults, demonstrating a plasma half-life of approximately one week and sustained GHRH-agonist activity. This remains the landmark peer-reviewed reference for the DAC formulation.
Key facts
- Reference
- Teichman et al., JCEM, 2006
- Population
- Healthy adult volunteers
- Key finding
- ~1-week half-life for DAC form
Study design
Randomised, placebo-controlled dose-escalation. Measured pharmacokinetics, GHRH-agonist activity, GH and IGF-1 responses at multiple time-points across a week.
Extended research context
The CJC-1295 & Ipamorelin deep dive
Deep dive: why CJC-1295 and Ipamorelin are studied together
CJC-1295 is a modified GHRH (growth-hormone-releasing hormone) analogue; Ipamorelin is a selective growth-hormone secretagogue that binds the ghrelin receptor (GHS-R1a). In pituitary-cell research models the two act on independent pathways whose downstream effect converges on GH release — CJC-1295 amplifies the endogenous GHRH signal while Ipamorelin adds a separate ghrelin-pathway stimulus. That's why supplier catalogues frequently package them together as a research reference blend.
DAC vs no-DAC: which CJC-1295 is which
'CJC-1295 with DAC' contains a Drug Affinity Complex (a Lys-maleimide moiety) that binds serum albumin and extends half-life to several days. 'CJC-1295 no-DAC' (also called Modified GRF 1-29) lacks the linker and clears in minutes. These are pharmacologically different peptides. A CoA must specify which form is in the vial; mass differs (~3,367 Da with DAC vs ~3,367 minus linker for no-DAC).
Ipamorelin's selectivity profile
Unlike earlier GHS-R agonists (e.g. GHRP-6), Ipamorelin was engineered for minimal cross-activity at cortisol- and prolactin-releasing pathways in research models. That receptor selectivity is why it is the reference secretagogue for controlled pituitary-cell studies.
Research applications
- ▸Pituitary-cell GH-release assays (comparator vs GHRH and hexarelin)
- ▸Half-life comparison studies: DAC vs no-DAC CJC-1295 forms
- ▸Ghrelin-receptor binding assays for Ipamorelin analogue development
- ▸Analytical HPLC method development for lipidated GHRH analogues
- ▸Stability testing under refrigerated storage
Handling checklist
- ✓Store lyophilised at −20 °C long-term
- ✓Reconstitute in bacteriostatic water; both peptides dissolve readily
- ✓Aliquot immediately, refrigerate at 2–8 °C, use within 28 days
- ✓Confirm salt form and DAC/no-DAC status on CoA before starting a study
- ✓Do not use for human administration — research reference only
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Confusing DAC and no-DAC CJC-1295
Fix: Check the CoA — the two have very different pharmacokinetics.
✗ Assuming Ipamorelin acts on GHRH receptors
Fix: It binds the ghrelin receptor (GHS-R1a) — a separate pathway from CJC-1295.
✗ Storing reconstituted solution at room temperature
Fix: Refrigerate 2–8 °C after reconstitution.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- Is CJC-1295 the same as Modified GRF 1-29?
- What is the difference between DAC and no-DAC CJC-1295?
- Does Ipamorelin raise cortisol?
- Why are CJC-1295 and Ipamorelin blended together?
- How long is the half-life of CJC-1295 with DAC?
Frequently asked questions
- Is 'Walker 2006' the same study?
- The commonly cited paper is Teichman et al. 2006; 'Walker' may refer to a co-author or a different citation.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedTeichman et al., JCEM 2006pubmed.ncbi.nlm.nih.gov
- PubMedRaun et al., Ipamorelin, the first selective GH secretagogue — Eur J Endocrinol 1998 (PMID 9849822)pubmed.ncbi.nlm.nih.gov
- PubMedSinha et al., Growth-hormone secretagogues — Endocr Rev (PMID 15855273)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · CJC-1295 (CID 16137828)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · Ipamorelin (CID 9831659)pubchem.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · GH-secretagogue trialsclinicaltrials.gov
- GuidelineGoogle — Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
Jack Muncaster · Founder, UK Peptides
Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.
More CJC-1295 & Ipamorelin articles
- CJC-1295 and Ipamorelin Storage HandlingCJC-1295 and ipamorelin storage: lyophilised at 2–8°C short-term, −20°C long-term. Reconstituted with bacteriostatic water and refrigerated for research handling.
- What Does CJC-1295 Stand For?CJC-1295 is a compound identifier from ConjuChem — the company that developed the peptide. 'CJC' derives from the developer name, '1295' is a compound code.
- Ipamorelin Molecular Weight and PropertiesIpamorelin molecular weight is approximately 711 Da. Pentapeptide with non-natural amino acids and C-terminal amide. Physicochemical summary.
- GHRH vs Ghrelin Pathways ExplainedGHRH and ghrelin are two distinct pathways to pituitary growth-hormone release. GHRH acts via the GHRH receptor; ghrelin via GHS-R1a. Both converge on somatotrophs.
- CJC-1295 in the Published LiteratureKey CJC-1295 references: Teichman et al. (JCEM 2006) and Ionescu & Frohman (JCEM 2006) reporting PK and endocrine responses of the DAC formulation.
Popular across the research hub
One flagship guide from every other research category — keep exploring.
- Retatrutide ResearchRetatrutide Receptor Binding: The Pharmacology
- GHK-Cu (Copper Peptide)What Is Copper Tripeptide-1?
- TB-500 (Thymosin β4 fragment)What Is the Actin-Binding Domain of TB-500?
- BPC-157 (Pentadecapeptide)BPC-157 Proline Structure and Synthesis
- Peptide ReferenceWhat Is HPLC Testing for Peptides?
- Bacteriostatic WaterWhat Is BAC Water?